148 related articles for article (PubMed ID: 27651323)
21. Protective role of erdosteine on vancomycin-induced oxidative stress in rat liver.
Sahin M; Cam H; Olgar S; Tunc SE; Arslan C; Uz E; Yilmaz HR
Mol Cell Biochem; 2006 Oct; 291(1-2):155-60. PubMed ID: 16733804
[TBL] [Abstract][Full Text] [Related]
22. Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.
Dal Negro R; Pozzi E; Cella SG
Pulm Pharmacol Ther; 2018 Dec; 53():80-85. PubMed ID: 30352285
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological effects of lysozyme on COPD and bronchial asthma with sputum: A randomized, placebo-controlled, small cohort, cross-over study.
Ohbayashi H; Setoguchi Y; Fukuchi Y; Shibata K; Sakata Y; Arai T
Pulm Pharmacol Ther; 2016 Apr; 37():73-80. PubMed ID: 26952317
[TBL] [Abstract][Full Text] [Related]
24. Dichloroacetate modulates the oxidative stress and inflammatory response to exercise in COPD.
Mercken EM; Calvert LD; Singh SJ; Hageman GJ; Schols AM; Steiner MC
Chest; 2009 Sep; 136(3):744-751. PubMed ID: 19395583
[TBL] [Abstract][Full Text] [Related]
25. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease.
Casaburi R; Maltais F; Porszasz J; Albers F; Deng Q; Iqbal A; Paden HA; O'Donnell DE;
Ann Am Thorac Soc; 2014 Nov; 11(9):1351-61. PubMed ID: 25289942
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study.
Crisafulli E; Coletti O; Costi S; Zanasi E; Lorenzi C; Lucic S; Fabbri LM; Bertini M; Clini EM
Clin Ther; 2007 Sep; 29(9):2001-9. PubMed ID: 18035199
[TBL] [Abstract][Full Text] [Related]
27. CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.
Rennard SI; Dale DC; Donohue JF; Kanniess F; Magnussen H; Sutherland ER; Watz H; Lu S; Stryszak P; Rosenberg E; Staudinger H
Am J Respir Crit Care Med; 2015 May; 191(9):1001-11. PubMed ID: 25695403
[TBL] [Abstract][Full Text] [Related]
28. Tissue-Protective Effect of Erdosteine on Multiple-Organ Injuries Induced by Fine Particulate Matter.
Cao L; Ping F; Zhang F; Gao H; Li P; Ning X; Cui G; Ma Z; Jiang X; Li S; Han S
Med Sci Monit; 2021 Dec; 27():e930909. PubMed ID: 34873140
[TBL] [Abstract][Full Text] [Related]
29. The effects of erdosteine, N-acetylcysteine, and vitamin E on nicotine-induced apoptosis of pulmonary cells.
Demiralay R; Gürsan N; Erdem H
Toxicology; 2006 Feb; 219(1-3):197-207. PubMed ID: 16377052
[TBL] [Abstract][Full Text] [Related]
30. Effect of the mucolytic erdosteine on the success rate of PPI-based first-line triple therapy for Helicobacter pylori eradication: a prospective, double-blind, randomized, placebo-controlled study.
Abut E; Yaşar B; Güveli H; Bölükbaş C; Bölükbaş FF; Dalay AR; Kurdaş OO
Scand J Gastroenterol; 2010 Jun; 45(6):677-83. PubMed ID: 20334478
[TBL] [Abstract][Full Text] [Related]
31. [ Erdosteine (Mucodox), oral administration].
J Pharm Belg; 2011 Jun; (2):55-6. PubMed ID: 21823444
[No Abstract] [Full Text] [Related]
32. [Multicenter, controlled, double-blind study of the efficacy and tolerance of Vectrine (erdostein) versus placebo in the treatment of stabilized chronic bronchitis with hypersecretion].
Aubier M; Berdah L
Rev Mal Respir; 1999 Sep; 16(4):521-8. PubMed ID: 10549062
[TBL] [Abstract][Full Text] [Related]
33. Six-minute walking-induced systemic inflammation and oxidative stress in muscle-wasted COPD patients.
van Helvoort HA; Heijdra YF; de Boer RC; Swinkels A; Thijs HM; Dekhuijzen PN
Chest; 2007 Feb; 131(2):439-45. PubMed ID: 17296645
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
[TBL] [Abstract][Full Text] [Related]
35. Use of mucolytics in COPD: A Delphi consensus study.
Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
[TBL] [Abstract][Full Text] [Related]
36. The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils.
Dal Sasso M; Bovio C; Culici M; Fonti E; Braga PC
Drugs Exp Clin Res; 2002; 28(4):147-54. PubMed ID: 12512232
[TBL] [Abstract][Full Text] [Related]
37. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine.
Oktem F; Arslan MK; Ozguner F; Candir O; Yilmaz HR; Ciris M; Uz E
Toxicology; 2005 Nov; 215(3):227-33. PubMed ID: 16112787
[TBL] [Abstract][Full Text] [Related]
38. Protective effect of erdosteine metabolite I against hydrogen peroxide-induced oxidative DNA-damage in lung epithelial cells.
Marabini L; Calò R; Braga PC
Arzneimittelforschung; 2011; 61(12):700-6. PubMed ID: 22282957
[TBL] [Abstract][Full Text] [Related]
39. Rehabilitation decreases exercise-induced oxidative stress in chronic obstructive pulmonary disease.
Mercken EM; Hageman GJ; Schols AM; Akkermans MA; Bast A; Wouters EF
Am J Respir Crit Care Med; 2005 Oct; 172(8):994-1001. PubMed ID: 16040783
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of erdosteine against hypochlorous acid-induced acute lung injury and lipopolysaccharide-induced neutrophilic lung inflammation in mice.
Hayashi K; Hosoe H; Kaise T; Ohmori K
J Pharm Pharmacol; 2000 Nov; 52(11):1411-6. PubMed ID: 11186250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
